Cost Insights: Breaking Down Teva Pharmaceutical Industries Limited and Alkermes plc's Expenses

Pharma Cost Trends: Teva vs. Alkermes (2014-2023)

__timestamp	Alkermes plc	Teva Pharmaceutical Industries Limited
Wednesday, January 1, 2014	447875000	9216000000
Thursday, January 1, 2015	483393000	8296000000
Friday, January 1, 2016	519270000	10044000000
Sunday, January 1, 2017	567637000	11560000000
Monday, January 1, 2018	601826000	10558000000
Tuesday, January 1, 2019	693218000	9351000000
Wednesday, January 1, 2020	572904000	8933000000
Friday, January 1, 2021	603913000	8284000000
Saturday, January 1, 2022	218108000	7952000000
Sunday, January 1, 2023	253037000	8200000000
Monday, January 1, 2024	245331000	8480000000

Cracking the code

Unveiling Cost Dynamics in the Pharmaceutical Sector

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for strategic decision-making. This analysis delves into the cost of revenue trends for Teva Pharmaceutical Industries Limited and Alkermes plc from 2014 to 2023. Over this period, Teva consistently reported higher costs, peaking in 2017 with a 25% increase from 2014, before a gradual decline. In contrast, Alkermes saw a 55% rise in costs by 2019, followed by a significant drop in 2022, reflecting a strategic shift or market adaptation. These trends highlight the dynamic nature of cost management in pharmaceuticals, influenced by factors such as market demand, regulatory changes, and innovation. As the industry faces increasing pressure to optimize costs while maintaining quality, these insights provide a valuable lens into the financial strategies of leading companies.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025